Checkpoint: PDUFA Date Catalyst Makes This A Must Watch (NASDAQ:CKPT)

DNA strand on scientific background

Rasi Bhadramani/iStock via Getty Images

Checkpoint Therapeutics (NASDAQ:CKPT) has made some great progress lately with respect to its advancement of its drug known as cosibelimab. That is, it has already been able to file a Biologics Licensing Application [BLA] to the

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *